Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data

BACKGROUND: Secukinumab, a fully human immunoglobulin G1-kappa monoclonal antibody that directly inhibits interleukin (IL)-17A, has been shown to have robust efficacy in the treatment of moderate-to-severe psoriasis (PsO), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) demonstrating a ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Deodhar, A., Mease, P. J., McInnes, I. B., Baraliakos, X., Reich, K., Blauvelt, A., Leonardi, C., Porter, B., Das Gupta, A., Widmer, A., Pricop, L., Fox, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498580/
https://www.ncbi.nlm.nih.gov/pubmed/31046809
http://dx.doi.org/10.1186/s13075-019-1882-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498580/
https://www.ncbi.nlm.nih.gov/pubmed/31046809
http://dx.doi.org/10.1186/s13075-019-1882-2

Ejemplares similares